Scandion Oncology develops drugs that specifically target chemotherapy resistance mechanisms. Improving the outcome and quality of life for cancer patients is Scandion’s mission.
Drug resistance is one of the most significant challenges for successful medical treatment in oncology. Currently, chemotherapy fails half of all cancer patients.
Although many cancer patients initially benefit from chemotherapy, a significant proportion develop resistance to chemotherapy drugs. Few of these patients survive.